Cancer Treatment - The 2nd Opinion that is Saving Lives
The data has now become clear that after initial chemotherapy fails, as many as 95% of cancer patients will not respond to the next suggested drug by conventional methods. There are now, new cancer diagnostic and treatment methods that may save your life or that of a loved one. Even the top cancer chemotherapy drugs are poisons to our bodies and are designed to attack and hopefully kill cancer cells, or at least slow cancer growth. Most of these treatments are extremely toxic to healthy cells and organs and many times poorly matched to the patient's individual cancer in their body. However, exciting new research is changing how we approach, characterize and treat cancers. It is also explaining why people have not been successful. The answer involves the science of biomarkers (genetic testing) and causation (what caused your cancer). Our medical group has been pioneering and specializing in this new treatment model to help patients with difficult and late stage cancers. We believe that this personalized combination is the best current targeted strategy for our patients.
Biomarkers are described as unique features and characteristics reflecting each patient's individual cancer (like a blue print of what your cancer will respond to)—this tells us which treatments are more likely to be effective, and more importantly, which treatments are likely to fail. When physicians utilize this information, the treatment strategies become targeted and designed specifically for the patient's own cancer genetics. Failed protocols and the one size fits all conventional cancer model costs millions of lives and trillions of dollars. Most of the success in conventional cancer treatment has only come from early surgical removal and early screening methods; making chemotherapy undesirable at best, however, the strength of biomarker matching changes this. In our experience, we commonly find patients that have been placed on the wrong chemotherapy and they experience all the side effects without the benefits. In our unique treatment program, we deliver genetically targeted and matched treatments in such small doses that patients mainly see benefits with hardly any side effects.
Research is leading the way in the science of biomarkers and targeting. In a pilot study, nine different cancer centers used molecular profiling on patients' tumors to identify potential biomarkers and help guide treatment for refractory cancer. Molecular targets were detected in nearly all of the patients, and of those where targets were found, 27% found success in secondary treatment options, allowing them to experience a longer, progression-free survival. That is just part of the story.
We provide true designer personalized cancer treatment, not simply new designer drugs that are touted by institutions like Mayo, MD Anderson, Sloan, Cancer Treatment Center's of America and others. Who cares about the drug if it's not a good match for you and your cancer! This new method takes drug companies and singular drug studies out of the equation and instead focuses on the patients' own cancer genetic information and unique metabolic shifts. The problem is that patients tend to follow the big cancer institutions and the conventional cancer treatment model until treatment fails or they are referred to hospice.
In the end, patients need good, viable cancer options, and this new cancer model provides a unique solution that has evolved out of an integrative medical setting with significant clinical experience. We believe this modern method of treating cancer helps reduce the risk of failing treatment and hones in on the best options for patients. If you have any questions about your options for cancer treatment, please feel free to contact us.
